Wednesday, April 9th, 2008
NexGen’s proprietary anti-cancer candidates include Prostaganin (targeting prostate cancer) and Tetanolic (targeting breast cancer) which have, in preliminary studies, shown to be able to target cancer cells without affecting normal tissue and therefore have potential to be developed into blockbuster drugs. These patented product candidates hold the potential to treat cancer in a way that is effective and safe for the patient. An exciting acquisition pipeline, including in oncology therapeutics, cancer vaccines and anti-bacterial drugs, ensures that the Company is constantly positioned as a leader in the forefront of developments in treating cancer and infectious disease. The Company is also evaluating up to four additional product candidates for acquisition. These biological products are targeted towards the treatment of cancer and infectious disease indications which represent significant unmet needs and significant ‘blockbuster’ markets. Further announcements will be made when possible.
The Company is evaluating the potential of a protein drug which has shown potency in preventing bacterial infection. This product has a novel mechanism of action and could potentially revolutionize the prevention of hospital acquired infections, such as MRSA or C.difficile. MRSA infections are becoming more prevalent in healthcare settings: in 1974, MRSA infections accounted for two percent of the total number of infections; in 1995 it was 22 percent; and in 2004 it was 63 percent (US Centers for Disease Control, 2007). The bacteria responsible are increasingly resistant to existing antibiotics. Other new product candidates being evaluated for potential acquisition include a number of biological products which enable the destruction of a broad range of solid tumors, including colorectal and ovarian cancers.
NextGen’s treatment niche is based on recent discoveries that indicate that most tumors are derived from a single cancer-initiating cell population which has stem cell properties (a cancer stem cell). With a Therapeutic Focus on Prostate, Breast, and Colorectal cancer NextGen intends to follow an outlicensing strategy, whereby programmes are outlicensed at preclinical, or Phase I, to organizations which have the necessary infrastructure to bring the products to market. All acquisition candidates are underpinned by patent applications or granted patents which confer protection in the major jurisdictions worldwide.
By outsourcing all product development work to established specialist service providers and Universities to add significant value, NextGen is able to keep operating costs to a minimum and at low cost. NextGen’s experienced Management team and Scientific Advisory Board will guide and direct development of the products to add maximum value.
Key Parameters
In summary, the combination of the following key parameters differentiates NextGen among biotechnology companies:
* Corporate focus is devoted to identification, evaluation and acquisition of drug targets and subsequent value addition to maximize benefits to stakeholders.
* World-class Management Team and Scientific Advisory Board directing product development and their specialist experience in this field.
* Potential value from the portfolio of pending patent applications for treatment of difficult to treat cancers (NextGen’s proprietary IP).
* Pipeline of acquisition candidates being evaluated, derived from global collaborations with other biotechnology companies and Universities.
* Strategy of acquiring candidates which target indications with significant unmet needs and blockbuster market potential
* Highly flexible organization and low fixed overheads due to outsourcing strategy.
* Leverage of resources through collaboration with well established service providers and academic laboratories
* Opportunistic approach characterized by swift decision making and ability to redirect research and business efforts quickly and at low cost, to maximize partnering activities.
Global Collaboration
On February 21 NextGen signed a Letter of Intent to come to a collaboration agreement with SymbioTec GmbH (”SymbioTec”), a German company that has developed and patented ONCOHIST, an effective and commercially attractive cancer-fighting compound. Cell culture and in vivo studies demonstrated that ONCOHIST is active against a variety of solid tumors like breast, ovarian and lung cancer as well as blood cancer types including drug-resistant cancers. Due to its unique mode of action and promising clinical outcomes, SymbioTec expects that ONCOHIST will act synergistically with several classes of approved cancer drugs in combination therapies or has the potential to replace current chemotherapies.
February 19 NextGen announced that it was in collaboration negotiations with Warburg Glycomed, a biopharmaceutical company that has developed a new class of drugs which has shown potent anti-cancer properties in animal models. Warburg Glycomed has a patent-protected compound that is able to reprogram cancer cells by modulating their aerobic glucose metabolism, which affects their ability to grow. Warburg Glycomed has expressed keen interest in collaborating with NextGen in a signed Letter of Intent.
NextGen Bioscience, Inc. (OTCBB:NXGB) is a London headquartered biotechnology company focused on the development and commercial licensure of novel therapeutic proteins that disrupt the advance of life-threatening cancers, with a concentration on prostate and breast cancer. NextGen leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies. All of NextGen’s proprietary product candidates target indications which are significant unmet needs and have blockbuster market potential. These acquisition candidates are underpinned by patent applications or granted patents which confer protection in the major jurisdictions worldwide.
NextGen’s target market, therapeutic cancer agents, is the largest disease market, exploding at a 20% growth rate each year and reaching a phenomenal global market volume of approximately $30 Billion. If Company discoveries prove successful, NextGen can expect up to $100 million in milestone payments per licensed product during clinical trials, and up to $400 million per annum in the years (up to 20 years) following commercialization. With market growth, NextGen’s licensing fees could grow to $700 million per annum per product. This represents a significant catalyst for company growth which will in turn greatly benefit stakeholders.
StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (469) 252-3030. Web: StockGuru.com. Email: Publisher@stockguru.com. Disclosure: Pentony Enterprises LLC has been compensated 37,000 shares from a non-controlling third party for profile coverage. Pentony Enterprises LLC is not a registered investment adviser or broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. It is the policy of Pentony Enterprises LLC to sell all shares of this and any company featured. Anyone considering any company we feature in consideration for free trading shares should consider this. Pentony Enterprises currently holds twenty one thousand shares.